Molecular selection: assignment criteria and innovative approaches
The choice of therapeutic tactics is not possible today without deep molecular profiling. Immunotherapy for breast cancer patients is prescribed based on PD-L1 biomarkers. This approach ensures maximum accuracy of the intervention, minimizing the systemic toxicity characteristic of classical chemotherapy.
A special place in the modern hierarchy of methods is occupied by innovative immunotherapy. Breast cancer in 2026 can be treated using antibody-drug conjugates (ADCs) and new inhibitors of immune control points. These drugs act synergistically, “opening“ the tumor cells to attack the patient’s own T-lymphocytes. In 2026, immunotherapy became an integral part of neoadjuvant (preoperative) care, which allows to significantly reduce the amount of surgical intervention.
Comparative characteristics of the methods
To objectively evaluate the effectiveness of different lines of therapy in 2026, the medical community uses comprehensive measures of relapse-free survival. A comparison of standard and immunological methods is given below.
|
Type of treatment |
Mechanism of action |
Clinical target |
Advantage of the method |
|
Targeted therapy |
Blockade of specific receptors |
HER2+ cells |
High selectivity |
|
PD-L1 inhibitors |
Removal of blocking from T-cell |
PD-L1 positive tumors |
Long-term relapse control |
|
ADC therapy |
Target delivery of cytostatics |
Cells with Trop-2/HER2 expression |
Dual mechanism of action |
|
Dendritic cell therapy |
Activation of antigen-presenting cells |
Wide range of antigens |
Formation of immune memory |
The usage of immunotherapy treatment for breast cancer in combination with targeted agents shows the highest survival rates in metastatic forms, shifting the disease toward a more favorable state of long-term stabilization.
The role of cell technologies: dendritic cell therapy
In 2026, significant progress is being made in the field of cellular immunology. Dendritic cell therapy has become a key element of personalized immunotherapy. Breast cancer in 2026 is increasingly treated with autologous vaccines to induce T-cell response against residual microscopic disease. The process involves taking the patient’s blood monocytes, their differentiation into dendritic cells in laboratory conditions, and “loading“ with tumor antigens. After being injected back into the body, these cells act as “instructors“ for the immune system, pointing T-killers to the hidden foci of the oncological process.
This technique is especially effective as immunotherapy and breast cancer prevention of relapses after removal of the primary tumor. Dendritic vaccines help the body recognize single circulating cancer cells that may have remained after surgery. Clinical data confirm that adding cell therapy to standard regimens reduces the risk of metastasis by 30-40% in high-risk groups.
Global availability and immunotherapy cost in Germany
Logistics and cost issues remain critical for patients. In 2026, the question of where to get immunotherapy for breast cancer finds its answer in specialized university clinics in Germany, where the most modern lines of immunotherapy are available to patients. This is due to the presence of certified GMP laboratories for growing dendritic cells and access to innovative drugs that are undergoing the final stages of clinical studies.
German clinics provide a full cycle of biological control of breast cancer, immunotherapy cost in Germany remains transparent and justified. For example, a course of dendritic cell therapy costs about €20,000 – €38,000, which includes a full cycle from cell separation to vaccine administration. For patients seeking immunotherapy for metastatic breast cancer, German cancer centers offer unique combined protocols that are not available in most other countries due to the complexity of laboratory control. The economic feasibility of such treatment is confirmed by the reduced need for long hospitalizations and the high quality of life of patients during therapy.
Specificity of immunotherapeutic effect in advanced forms
The leading vector in changing prognosis for patients with advanced forms of cancer was immunotherapy. Breast cancer treatment using checkpoint inhibitors turns the aggressive course of the disease into a state of controlled chronic process. Unlike chemotherapy, immunotherapy works cumulatively. This means that the immune response can continue to work even after the active phase of drug administration is complete.
In 2026, clinicians pay particular attention to the phenomenon of pseudo-progression, where the tumor may initially appear larger due to the influx of immune cells, which requires highly qualified radiologists to correctly interpret the results. That is why immunotherapy should be carried out in centers with extensive experience in managing such patients, where doctors are able to recognize immune-mediated undesirable phenomena in time and adjust the dosage.
Organization of treatment abroad with the help of Booking Health
Navigation in the types of high-tech medical services requires professional support. The Booking Health company provides patients with access to leading European cancer centers that specialize in innovative immunotherapy. Breast cancer programs are implemented using the latest clinical studies. We understand that with breast cancer, the time factor is decisive, so we provide the fastest possible appointment with specialized specialists.
Thanks to direct contacts with hospitals, Booking Health guarantees transparency of costs for immunotherapy for breast cancer patients and provides insurance in case of additional medical needs. Our goal in 2026 – is to make innovations (such as dendritic vaccines) available to every woman, regardless of her geographic location. We accompany the patient at every step, providing the highest level of medical service and professional support in the fight for health.